KRAS and Pancreatic Cancer: Entering a New Era of Treatment

For the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma, more than 90% of tumors are thought to have a KRAS mutation. For decades, these mutations were considered “undruggable,” meaning there was no effective way to target them with treatments. But groundbreaking research has changed that with remarkable results – a new RAS inhibitor approximately doubled overall survival compared with chemotherapy in patients with metastatic pancreatic cancer.

Join PanCAN to discuss the current moment in KRAS research – and what the newest discoveries may mean for patients now and in the future. During our free virtual event, hosted by PanCAN Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc, you'll learn more about:

• What KRAS is and why it's critical for patients diagnosed with pancreatic cancer to know if their tumor has a KRAS mutation
• The latest research related to KRAS and beyond, including clinical trials happening now that stand to change the treatment landscape
• The important role patients play in advocating for biomarker testing, clinical trials and new treatment options for KRAS-driven cancers
• How PanCAN Patient Services can help patients get biomarker testing to identify KRAS and other mutations as well as navigate treatment options, including clinical trials

Anna Berkenblit, MD, MMSc

PanCAN Chief Scientific and Medical Officer responsible for the organization’s overall scientific and clinical strategy, including PanCAN-sponsored studies, research grants, health data, business development, and patient services

Ignacio Garrido-Laguna, MD, PhD, MBA

Oncologist and chair of the Department of Early Therapeutics Development at Moffitt Cancer Center

Kirsten L. Bryant, PhD

Assistant Professor, Department of Pharmacology; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Terri Conneran

Founder, KRAS Kickers; Director, KRAS Cancer Connect; KRAS G12D non-small cell lung cancer survivor and patient advocate

Sydney Rathjens, MHI

Senior Manager, PanCAN Patient Services, Research and Education

*PanCAN does not endorse any company, product, test or drug. All topics discussed during this webinar are for informational purposes only and should not be considered medical advice. Contact PanCAN Patient Services and your healthcare team to learn more.